Program
Benzoyl Peroxide
Also written as “Adapalene/Benzoyl Peroxide”, “Adapalene and Benzoyl Peroxide Gel” and “Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%”.
Its studies are mostly in Acne Vulgaris · Herpes Simplex · Skin Diseases, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 90 open or running | phase 4since Feb 4, 2009 | Jul 7, 2008 | none ahead |
| Galderma Group | 70 open or running | phase 4since Apr 30, 2008 | Jan 11, 2007 | none ahead |
| Sun Pharmaceutical Industries | 40 open or running | phase 1since Dec 3, 2012 | Dec 3, 2012 | none ahead |
| Teva Pharmaceutical Industries | 30 open or running | phase 3since Feb 7, 2013 | Feb 7, 2013 | none ahead |
| Padagis | 20 open or running | phase 3since Jul 31, 2015 | Jul 31, 2015 | none ahead |
| Zurita Laboratorio Farmaceutico Ltda. | 20 open or running | phase 4since Dec 13, 2010 | Apr 6, 2009 | none ahead |
| Greg Bew | 11 open or running | phase 2since Jun 16, 2025 | Jun 16, 2025 | Jan 2027phase 2 · NCT07032649 |
Also a collaborator on its studies: proinnovera-gmbh, rho-inc and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Jan 11, 2007.
- Jun 16, 2011Phase 1 study in Acne VulgarisGlaxoSmithKline · NCT01428466 · 20 enrolled · Japan
- Dec 3, 2012Sun Pharmaceutical Industries's first study: phase 1 study in Acne VulgarisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01742637 · 2,008 enrolled
- Jan 14, 2013Phase 1 study in Acne VulgarisSun Pharmaceutical Industries · NCT01769235 · 1,215 enrolled
- Feb 7, 2013Teva Pharmaceutical Industries's first study: phase 3 study in Acne VulgarisNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT01788384 · 708 enrolled
- Jan 30, 2014Phase 4 study in Skin DiseasesGlaxoSmithKline · NCT02052752 · 90 enrolled · United States
- Feb 20, 2014Phase 2 study in Acne VulgarisGalderma Group · NCT02073461 · 236 enrolled · Japan
- Jul 31, 2015Padagis's first study: phase 3 study in Acne VulgarisNew to PadagisPadagis · NCT02515305 · 890 enrolled · United States
- Aug 14, 2015Phase 3 study in Acne VulgarisPadagis · NCT02525549 · 903 enrolled
- Oct 14, 2015Phase 1 study in Acne VulgarisSun Pharmaceutical Industries · NCT02578043 · 844 enrolled
- Oct 23, 2015Phase 4 study in Acne VulgarisGalderma Group · NCT02589405 · 50 enrolled · Germany
- Nov 1, 2015Phase 1 study in Acne VulgarisSun Pharmaceutical Industries · NCT02595034 · 1,000 enrolled
- Nov 25, 2015Phase 3 study in Acne VulgarisTeva Pharmaceutical Industries · NCT02616614 · 862 enrolled · United States
- Jan 5, 2016Phase 3 study in Acne VulgarisTeva Pharmaceutical Industries · NCT02651220 · 1,001 enrolled · United States, Belize
- Jun 16, 2025Greg Bew's first study: phase 2 study in Herpes SimplexNew to Greg BewGreg Bew · NCT07032649 · 100 planned · United States
Ahead
- Jan 2027Primary completion: phase 2 study in Herpes SimplexGreg Bew · NCT07032649
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07032649Herpes Simplex · United States | 2 | Not yet recruiting | Greg Bew | Jan 2027 | 100 |
| NCT02651220Acne Vulgaris · United States, Belize | 3 | Completed | Teva Pharmaceutical Industries | Apr 2016 | 1,001 |
| NCT02616614Acne Vulgaris · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 2015 | 862 |
| NCT02595034Acne Vulgaris | 1 | Completed | Sun Pharmaceutical Industries | Oct 2015 | 1,000 |
| NCT02589405Acne Vulgaris · Germany | 4 | Completed | Galderma Group | Jan 2016 | 50 |
| NCT02578043Acne Vulgaris | 1 | Completed | Sun Pharmaceutical Industries | Aug 2015 | 844 |
| NCT02525549Acne Vulgaris | 3 | Completed | Padagis | Aug 2012 | 903 |
| NCT02515305Acne Vulgaris · United States | 3 | Completed | Padagis | Apr 2016 | 890 |
| NCT02073461Acne Vulgaris · Japan | 2 | Completed | Galderma Group | Oct 2014 | 236 |
| NCT02052752Skin Diseases · United States | 4 | Completed | GlaxoSmithKline | May 2014 | 90 |
| NCT01788384Acne Vulgaris | 3 | Completed | Teva Pharmaceutical Industries | Dec 2012 | 708 |
| NCT01769235Acne Vulgaris | 1 | Completed | Sun Pharmaceutical Industries | Sep 2013 | 1,215 |
| NCT01742637Acne Vulgaris | 1 | Completed | Sun Pharmaceutical Industries | Feb 2014 | 2,008 |
| NCT01428466Acne Vulgaris · Japan | 1 | Completed | GlaxoSmithKline | Feb 15, 2011 | 20 |
| NCT01260571Treatment of Acne Vulgaris Grade II in a Short Period of Time. · Brazil | 4 | UNKNOWN | Zurita Laboratorio Farmaceutico Ltda. | Mar 2011 | 62 |
| NCT01138735Acne Vulgaris · United States, Canada | 4 | Completed | Galderma Group | Aug 2011 | 285 |
| NCT00964366Acne Vulgaris · United States | 4 | Completed | GlaxoSmithKline | Aug 2009 | 53 |
| NCT00964223Acne Vulgaris · United States | 4 | Completed | GlaxoSmithKline | Nov 2009 | 28 |
| NCT00926367Acne Vulgaris · United States | 4 | Completed | GlaxoSmithKline | Jun 2009 | 52 |
| NCT00887484Acne Vulgaris · Argentina | 4 | Completed | GlaxoSmithKline | Jun 2009 | 50 |
| NCT00877409Acne Vulgaris · Brazil | 3 | UNKNOWN | Zurita Laboratorio Farmaceutico Ltda. | Jul 2009 | 80 |
| NCT00837213Acne Vulgaris · United States | 4 | Completed | GlaxoSmithKline | Aug 2008 | 33 |
| NCT00776919Acne Vulgaris · United States, Belize, Canada | 3 | Completed | GlaxoSmithKline | Sep 2009 | 1,315 |
| NCT00713609Acne Vulgaris · United States | 2 | Completed | GlaxoSmithKline | Mar 2009 | 591 |
| NCT00671749Acne Vulgaris · United States | 4 | Completed | Galderma Group | Aug 2008 | 100 |
| NCT00446043Acne Vulgaris · United States | 3 | Completed | Galderma Group | May 23, 2005 | 452 |
| NCT00422240Acne Vulgaris · United States | 3 | Completed | Galderma Group | Jul 12, 2007 | 1,668 |
| NCT00421993Acne Vulgaris · United States, Canada, Germany and more | 3 | Completed | Galderma Group | Oct 2007 | 1,670 |
How it is read
Names in the registry
- “Adapalene/Benzoyl Peroxide”, 3 entries
- “Adapalene and Benzoyl Peroxide Gel”, 2 entries
- “Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%”, 2 entries
- “Benzoyl Peroxide 10% Bar”, 1 entry
- “Benzoyl Peroxide Gel 2.5%”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 29 studies
- Herpes Simplex, 1 study
- Skin Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.